BioCentury | Nov 10, 2017
Financial News

Telix raises A$50M in Australian IPO

...January, Telix gained exclusive rights to girentuximab from Heidelberg Pharma AG (Xetra:WL6), formerly known as Wilex AG...
BioCentury | Nov 9, 2017
Financial News

Telix raises A$50M in Australian IPO

...January, Telix gained exclusive rights to girentuximab from Heidelberg Pharma AG (Xetra:WL6), formerly known as Wilex AG. Jennie...
BioCentury | Feb 10, 2017
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

...HDP-101 as the lead compound and said it expects to begin clinical trials in 2018. Wilex...
...BioCentury, Sept. 26, 2016 ). Max Delbrück Center for Molecular Medicine Berlin-Buch , Berlin, Germany Wilex AG...
BioCentury | Jan 20, 2017
Company News

Wilex, Telix deal

...clear cell renal cell carcinoma (RCC). Telix is responsible for all development and commercialization costs. Wilex...
...and will evaluate the use of carbonic anhydrase IX (CAIX)-targeting therapeutic agents for cancer-related malignancies. Wilex...
...company that was launched earlier this month. The companies declined to disclose additional financial terms. Wilex AG...
BioCentury | Oct 31, 2016
Company News

Nordic Nanovector, Wilex deal

...Nordic Nanovector and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to develop antibody-drug conjugates (ADCs) to treat...
...lymphoma (NHL). The companies declined to disclose financial terms. Nordic Nanovector ASA (OSE:NANO), Oslo, Norway Wilex AG...
BioCentury | Oct 17, 2016
Financial News

Financial News

Wilex AG WIR Staff...
BioCentury | Sep 26, 2016
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

...The Max Delbrueck Center ( MDC ) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to...
...antibody targeted amanitin conjugates (ATAC) technology to start in 2018 to treat multiple myeloma (MM). Wilex...
...did not respond to inquiries. Max Delbrueck Center for Molecular Medicine Berlin-Buch , Berlin, Germany Wilex AG...
BioCentury | Jun 27, 2016
Company News

Advanced Proteome Therapeutics, Wilex deal

...Advanced Proteome and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to create antibody-drug conjugates (ADCs) to treat...
...the deal and declined to disclose financial terms. Advanced Proteome Therapeutics Corp. (TSX-V:APC;FSE:0E8), Boston, Mass. Wilex AG...
BioCentury | May 2, 2016
Financial News

Wilex completes rights offering

Wilex AG (Xetra:WL6), Munich, Germany Business: Cancer Date completed: 2016-04-25 Type: Rights offering Raised: EUR4.1 million ($4.7 million) Shares: 2.2 million Price: EUR1.84 Shares after offering: 12.9 million Investor: Existing investors Note: Shareholders were eligible...
BioCentury | Apr 11, 2016
Financial News

Wilex proposes rights offering

Wilex AG (Xetra:WL6), Munich, Germany Business: Cancer Date announced: 2016-04-04 Type: Rights offering To be raised: Up to EUR4.1 million ($4.7 million) Shares: 2.2 million Price: EUR1.84 Shares outstanding prior: 10.7 million Investor: Existing investors...
Items per page:
1 - 10 of 293
BioCentury | Nov 10, 2017
Financial News

Telix raises A$50M in Australian IPO

...January, Telix gained exclusive rights to girentuximab from Heidelberg Pharma AG (Xetra:WL6), formerly known as Wilex AG...
BioCentury | Nov 9, 2017
Financial News

Telix raises A$50M in Australian IPO

...January, Telix gained exclusive rights to girentuximab from Heidelberg Pharma AG (Xetra:WL6), formerly known as Wilex AG. Jennie...
BioCentury | Feb 10, 2017
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

...HDP-101 as the lead compound and said it expects to begin clinical trials in 2018. Wilex...
...BioCentury, Sept. 26, 2016 ). Max Delbrück Center for Molecular Medicine Berlin-Buch , Berlin, Germany Wilex AG...
BioCentury | Jan 20, 2017
Company News

Wilex, Telix deal

...clear cell renal cell carcinoma (RCC). Telix is responsible for all development and commercialization costs. Wilex...
...and will evaluate the use of carbonic anhydrase IX (CAIX)-targeting therapeutic agents for cancer-related malignancies. Wilex...
...company that was launched earlier this month. The companies declined to disclose additional financial terms. Wilex AG...
BioCentury | Oct 31, 2016
Company News

Nordic Nanovector, Wilex deal

...Nordic Nanovector and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to develop antibody-drug conjugates (ADCs) to treat...
...lymphoma (NHL). The companies declined to disclose financial terms. Nordic Nanovector ASA (OSE:NANO), Oslo, Norway Wilex AG...
BioCentury | Oct 17, 2016
Financial News

Financial News

Wilex AG WIR Staff...
BioCentury | Sep 26, 2016
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

...The Max Delbrueck Center ( MDC ) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to...
...antibody targeted amanitin conjugates (ATAC) technology to start in 2018 to treat multiple myeloma (MM). Wilex...
...did not respond to inquiries. Max Delbrueck Center for Molecular Medicine Berlin-Buch , Berlin, Germany Wilex AG...
BioCentury | Jun 27, 2016
Company News

Advanced Proteome Therapeutics, Wilex deal

...Advanced Proteome and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to create antibody-drug conjugates (ADCs) to treat...
...the deal and declined to disclose financial terms. Advanced Proteome Therapeutics Corp. (TSX-V:APC;FSE:0E8), Boston, Mass. Wilex AG...
BioCentury | May 2, 2016
Financial News

Wilex completes rights offering

Wilex AG (Xetra:WL6), Munich, Germany Business: Cancer Date completed: 2016-04-25 Type: Rights offering Raised: EUR4.1 million ($4.7 million) Shares: 2.2 million Price: EUR1.84 Shares after offering: 12.9 million Investor: Existing investors Note: Shareholders were eligible...
BioCentury | Apr 11, 2016
Financial News

Wilex proposes rights offering

Wilex AG (Xetra:WL6), Munich, Germany Business: Cancer Date announced: 2016-04-04 Type: Rights offering To be raised: Up to EUR4.1 million ($4.7 million) Shares: 2.2 million Price: EUR1.84 Shares outstanding prior: 10.7 million Investor: Existing investors...
Items per page:
1 - 10 of 293